Non-Small Cell Lung Cancer (NSCLC)

EMPOWER-Lung 1: Cemiplimab Shows Sustained 5-Year Survival Benefit in Advanced NSCLC

Five-year OS probability was 29.0% for cemiplimab and 15.0% for chemotherapy in advanced NSCLC patients with ≥50% PD-L1 expression.

Zipalertinib demonstrated 27.4% response rate in EGFR ex20ins NSCLC patients post-amivantamab with 8.5-month duration of...

ANKTIVA reverses lymphopenia in 80% of checkpoint-resistant NSCLC patients, extending survival to 21.1 months in...

Tagrisso plus chemo shows 47.5 months median OS vs 37.6 months monotherapy in EGFR+ lung...

60-85% of NSCLC patients develop secondary resistance to ICIs, creating critical unmet need requiring novel...

Screening effectiveness varies by histology, with adenocarcinoma showing 17.8-23.0% mortality reduction across trials.

Zongertinib becomes first oral HER2-targeted therapy for NSCLC, achieving 75% response rate in previously treated...

FDA grants Breakthrough Therapy Designation to izalontamab brengitecan for previously treated EGFR-mutated NSCLC patients.

ctDNA kinetics guide treatment intensification in NSCLC, achieving 11.0-month median PFS with less platinum exposure...

"Steroids were the biggest predictor of why certain immunotherapies may not be effective" - Dr....

Perioperative nivolumab continued to demonstrate event-free survival benefits versus placebo in patients with resectable NSCLC.

FDA approves sunvozertinib for NSCLC with EGFR exon20 insertion mutations - first oral targeted therapy...